TY - JOUR
T1 - Lobular carcinomas in situ display intralesion genetic heterogeneity and clonal evolution in the progression to invasive lobular carcinoma
AU - Lee, Ju Youn
AU - Schizas, Michail
AU - Geyer, Felipe C.
AU - Selenica, Pier
AU - Piscuoglio, Salvatore
AU - Sakr, Rita A.
AU - Ng, Charlotte K.Y.
AU - Scarpa Carniello, Jose V.
AU - Towers, Russell
AU - Giri, Dilip D.
AU - de Andrade, Victor P.
AU - Papanastasiou, Anastasios D.
AU - Viale, Agnes
AU - Harris, Reuben S.
AU - Solit, David B.
AU - Weigelt, Britta
AU - Reis-Filho, Jorge S.
AU - King, Tari A.
N1 - Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2019/1/15
Y1 - 2019/1/15
N2 - PURPOSE: Lobular carcinoma
in situ (LCIS) is a preinvasive lesion of the breast. We sought to define its genomic landscape, whether intralesion genetic heterogeneity is present in LCIS, and the clonal relatedness between LCIS and invasive breast cancers.
Experimental Design: We reanalyzed whole-exome sequencing (WES) data and performed a targeted amplicon sequencing validation of mutations identified in 43 LCIS and 27 synchronous more clinically advanced lesions from 24 patients [9 ductal carcinomas
in situ (DCIS), 13 invasive lobular carcinomas (ILC), and 5 invasive ductal carcinomas (IDC)]. Somatic genetic alterations, mutational signatures, clonal composition, and phylogenetic trees were defined using validated computational methods.
RESULTS: WES of 43 LCIS lesions revealed a genomic profile similar to that previously reported for ILCs, with
CDH1 mutations present in 81% of the lesions. Forty-two percent (18/43) of LCIS were found to be clonally related to synchronous DCIS and/or ILCs, with clonal evolutionary patterns indicative of clonal selection and/or parallel/branched progression. Intralesion genetic heterogeneity was higher among LCIS clonally related to DCIS/ILC than in those nonclonally related to DCIS/ILC. A shift from aging to APOBEC-related mutational processes was observed in the progression from LCIS to DCIS and/or ILC in a subset of cases.
CONCLUSIONS: Our findings support the contention that LCIS has a repertoire of somatic genetic alterations similar to that of ILCs, and likely constitutes a nonobligate precursor of breast cancer. Intralesion genetic heterogeneity is observed in LCIS and should be considered in studies aiming to develop biomarkers of progression from LCIS to more advanced lesions.
AB - PURPOSE: Lobular carcinoma
in situ (LCIS) is a preinvasive lesion of the breast. We sought to define its genomic landscape, whether intralesion genetic heterogeneity is present in LCIS, and the clonal relatedness between LCIS and invasive breast cancers.
Experimental Design: We reanalyzed whole-exome sequencing (WES) data and performed a targeted amplicon sequencing validation of mutations identified in 43 LCIS and 27 synchronous more clinically advanced lesions from 24 patients [9 ductal carcinomas
in situ (DCIS), 13 invasive lobular carcinomas (ILC), and 5 invasive ductal carcinomas (IDC)]. Somatic genetic alterations, mutational signatures, clonal composition, and phylogenetic trees were defined using validated computational methods.
RESULTS: WES of 43 LCIS lesions revealed a genomic profile similar to that previously reported for ILCs, with
CDH1 mutations present in 81% of the lesions. Forty-two percent (18/43) of LCIS were found to be clonally related to synchronous DCIS and/or ILCs, with clonal evolutionary patterns indicative of clonal selection and/or parallel/branched progression. Intralesion genetic heterogeneity was higher among LCIS clonally related to DCIS/ILC than in those nonclonally related to DCIS/ILC. A shift from aging to APOBEC-related mutational processes was observed in the progression from LCIS to DCIS and/or ILC in a subset of cases.
CONCLUSIONS: Our findings support the contention that LCIS has a repertoire of somatic genetic alterations similar to that of ILCs, and likely constitutes a nonobligate precursor of breast cancer. Intralesion genetic heterogeneity is observed in LCIS and should be considered in studies aiming to develop biomarkers of progression from LCIS to more advanced lesions.
UR - http://www.scopus.com/inward/record.url?scp=85060045931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060045931&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-18-1103
DO - 10.1158/1078-0432.CCR-18-1103
M3 - Article
C2 - 30185420
AN - SCOPUS:85060045931
SN - 1078-0432
VL - 25
SP - 674
EP - 686
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 2
ER -
